So, Albert, thank you so much for joining us on this very special day for you at Pfizer. You had your first quarter results out, which were strong and beat estimates. As you look at those results.Why do you think you beat the estimates and what does it tell you about the rest of the year. Well, it's about execution. We were very focused and our commercial investing, which is basically the reflection of these commercial results, is one of a kind.They are very, very good. They understand the customer. They un ...

We were reviewing with our board uh the first molecule that we were able to completely design through AI just two weeks ago and uh 3 months ago we wouldn't be able to do it and 3 months later we have already a molecule already designed right in the face but also I want to say that when it speaks about AI there are two different uh areas one it is what technology can do now and cannot do everything But clearly can do much more than we are using to. And the bottleneck for something like that is not technologi ...

I'LL SEND IT BACK TO YOU. >> IT'S INTERESTING. HE ACTUALLY THINKS THE BID MIGHT BE REAL.IT'S NOT SURPRISING. ALL RIGHT. THANK YOU.CONTESSA. THE FDA HAS BEEN UNDER FIRE RECENTLY. PATIENTS, ONCOLOGISTS AND BIOTECH INVESTORS HAVE BEEN PRESSING COMMISSIONER DOHERTY MCCAREY OVER A STRING OF DRUG REJECTIONS, NONE MORE CONTENTIOUS THAN REPLIMUNE.THAT'S A HAS A CANCER THERAPY FOR MELANOMA PATIENTS THAT BACKERS SAY PUTS A THIRD OF PATIENTS INTO MULTI-YEAR REMISSIONS. AND THE ORIGINAL REVIEW TEAM AT THE FDA DID SEEM ...

BioNTech plans to halt operations at several manufacturing sites, affecting as many as 1,860 jobs, due to dwindling demand for its Covid-19 vaccine https://t.co/2CsN8xq9F7 ...

Pfizer reports first quarter sales that beat estimates as demand for older blockbusters helped to offset a decline in revenues from Covid products https://t.co/p6yEwSalas ...

Biopharma is rebounding across rare disease, oncology and neuroscience. Here, Cytokinetics achieved a rare milestone: a first FDA approval after 27 years of development. https://t.co/tPZKCxLF8j ...

Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug development. https://t.co/he7YfIMlD0 ...

Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug development. https://t.co/lzAcv7ORKv ...

- There's definitely a point where you're just like, I'm going to have to live like this forever. - I've been on antidepressants since I was 13 year and never really got away from depression. - Spravato has become a big success for Johnson and - Johnson.The patient will feel sleepy. They will feel as though they're floating. They can feel detached from themselves.That's the physical part of this treatment. The patient's psychological response differs, and there's very few things I can do to prepare patients ...

Even if you aren't familiar with the name Abby, you've probably seen some of their commercials. >> There's nothing like clearer skin and better movement. >> This week, the company delivered a solid earnings beat driven by its immunology portfolio of drugs that sent the stock up, recovering from recent losses.Yet, investors, they remain on edge. Aby is the undisputed titan of the hundred billion dollar autoimmune disease market. It treats conditions like psoriasis, arthritis, Crohn's disease.For over two dec ...